C12Y 304/22069
Sars coronavirus main proteinase
Official title: SARS coronavirus main proteinase (3.4.22.69)
C12Y304/22069 (Sars coronavirus main proteinase) appears on 1 US grants and 11 published applications in this corpus.
Search patents in C12Y- Granted patents
- 1
- Published applications
- 11
- Assignees
- 8
- Inventors
- 28
- Latest grant
- 29 Apr 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2022 | 0 | 1 |
| 2023 | 0 | 4 |
| 2024 | 0 | 3 |
| 2025 | 1 | 2 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Drug containing active sulfur compound as its main component25 Jun 2026US 2026/0174827 A1Bio-Xcelerator, Inc.
- Methods and compositions11 Sep 2025US 2025/0283066 A1United Kingdom Research and Innovation
- Predictive model for variants associated with drug resistance and theranostic applications thereof24 Jul 2025US 2025/0237642 A1
- Methods and proteins for targeting main protease of coronavirus16 May 2024US 2024/0161865 A1
- Drug containing active sulfur compound as its main component2 May 2024US 2024/0139277 A1Bio-Xcelerator, Inc.
Most cited
By later US patents
No patent in this class has been cited by a later US patent yet.